Related Experiment Video
Updated: Jan 26, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
Published on: August 1, 2013
CD91 on dendritic cells governs immunosurveillance of nascent, emerging tumors
Abigail L Sedlacek1, Theodore P Younker2, Yu Jerry Zhou3
1Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Abstract:
The immune system detects aberrant, premalignant cells and eliminates them before the development of cancer. Immune cells, including T cells, have been shown to be critical components in eradicating these aberrant cells, and when absent in the host, incidence of cancer increases. Here, we show that CD91, a receptor expressed on antigen-presenting cells, is required for priming immune responses to nascent, emerging tumors. In the absence of CD91, effector immune responses are subdued, and tumor incidence and progression are amplified. We also show that, consequently, tumors that arise in the absence of CD91 express neo-epitopes with indices that are indicative of greater immunogenicity. Polymorphisms in human CD91 that are expected to affect ligand binding are shown to influence antitumor immune responses in cancer patients. This study presents a molecular mechanism for priming immune responses to nascent, emerging tumors that becomes a predictor of cancer susceptibility and progression.
Insights
The immune system uses CD91 (cluster of differentiation 91) to detect and eliminate early cancer cells. Its absence amplifies tumor growth and progression, highlighting CD91
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- The immune system, particularly T cells, plays a crucial role in preventing cancer by eliminating aberrant cells.
- Deficiencies in immune surveillance are linked to increased cancer incidence.
- Antigen-presenting cells (APCs) are key mediators of immune responses against nascent tumors.
Purpose of the Study:
- To investigate the role of CD91 (cluster of differentiation 91) in immune responses to nascent tumors.
- To elucidate the molecular mechanism by which CD91 influences cancer immunosurveillance.
- To determine if CD91 function impacts tumor immunogenicity and patient outcomes.
Main Methods:
- Utilized mouse models to study the role of CD91 in tumor development and immune responses.
- Analyzed immune cell activity and effector functions in the presence and absence of CD91.
- Examined tumor neo-epitope expression and immunogenicity.
- Investigated the impact of human CD91 polymorphisms on antitumor immunity in cancer patients.
Main Results:
- CD91 is essential for priming effective immune responses against emerging tumors.
- Absence of CD91 leads to suppressed effector immune responses and increased tumor incidence and progression.
- Tumors developing without CD91 exhibit enhanced immunogenicity due to altered neo-epitope expression.
- Human CD91 polymorphisms correlate with altered antitumor immune responses in cancer patients.
Conclusions:
- CD91 acts as a critical receptor for initiating immune surveillance against nascent tumors.
- CD91 deficiency compromises the immune system's ability to control early-stage cancer.
- CD91's role in priming antitumor immunity makes it a potential predictor of cancer susceptibility and progression.
More Related Videos
Related Concept Videos
Emerging Adulthood
Neurons: The Cell Body and the Dendrites
Physical Principles Governing Gas Exchange
Gas Laws Governing Respiration
The behavior of gases is guided by Dalton's Law of partial pressures and Henry's Law.
Dalton's Law asserts that the total...
Introduction Cardiac Emergencies
Drug Control Governance: Regulatory Bodies and Their Impact
Applications of GIS: Disaster Management and Emergency Response

